Abstract
Peripheral T-cell lymphoma (PTCL) is a group of rare and highly heterogeneous lymphoid malignancies. Although the incidence of PTCL is much lower than that of B-cell lymphoma, PTCL has a poorer prognosis. So far, no standard treatment has been established, which account for dismal long-term survival rate. In recent years, a number of novel agents and therapeutic regimens have shown promise in the treatment of PTCL. This review focuses on the new treatment progress of PTCL, in order to increase the reference for clinical work. Key words: Lymphomas, T-cell, peripheral; Drug therapy; Drug approval; Clinical trial
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Blood Transfusion and Hematology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
